FinBoss.io
CSEN
  • Home
  • Crypto prices
  • Bitcoin on-chain
  • US macro
  • US stocks
  • Guides
  • How we make money
FinBoss.io
Home
Crypto prices
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Guides
How we make money
CSEN
Home
Stocks
Boston Scientific Corp
BS

Boston Scientific Corp

BSXHealth care

Stock · Data from SEC EDGAR 13F · Held by 18 of 87 tracked investors

$45.69
▼ 0.70%
Famous investorshold 18buying 0selling 1
Price (USD)
$45.69
Market cap
$66.2B
P/E ratio
18.5
Tracked investors holding
18 of 87
Next earnings
28 Oct 2026

Boston Scientific Corp at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
78out of 100
  • Valuation75
  • Growth81
  • Profitability79
  • Quality78
  • Debt54
  • Stability100
In its favour

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 202629 Jul 20260.860.83+3.6%
Mar 202622 Apr 20260.800.800%
Dec 20254 Feb 20260.800.78+2.6%
Sep 202522 Oct 20250.750.71+5.6%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

7D
+2.93%
1M
+2.26%
3M
+3.25%
YTD
-51.76%
1Y
-54.81%
3Y
-7.73%
5Y
+5.94%
Forward P/E
13.5
Dividend yield
–
52-week low
$41.39
52-week high
$105.65

Chart BSX

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

18
LA
Lee Ainslie
Maverick Capital
2.24%$253,414,762▲ +41.5%
JS
Jim Simons
Renaissance Technologies
0.14%$102,944,373▼ -23.5%
CA
Cliff Asness
AQR Capital Management
0.14%$413,217,118▲ +84.8%
LB
Louis Bacon
Moore Capital Management
0.12%$8,077,446New position
Čn
Česká národní banka
Česká národní banka
0.1%$18,175,816▼ -1.6%
LR
Larry Robbins
Glenview Capital
0.09%$4,826,937New position
PT
Paul Tudor Jones
Tudor Investment Corp
0.09%$63,065,547▲ +133.6%
Ns
Norský státní fond
Norges Bank
0.09%$903,536,838New position
Šn
Švýcarská národní banka
Swiss National Bank
0.09%$178,906,024▼ -3.7%
RD
Ray Dalio
Bridgewater Associates
0.08%$18,866,096▲ +474.1%
IE
Israel Englander
Millennium Management
0.08%$210,735,360▲ +25.4%
JG
Joel Greenblatt
Gotham Asset Management
0.04%$15,992,537▼ -22.4%
GI
Generali Investments CEE
Generali Investments CEE
0.04%$853,600unchanged
KG
Ken Griffin
Citadel Advisors
0.02%$212,877,084▲ +18.3%
SC
Steven Cohen
Point72 Asset Management
0.02%$15,588,486▼ -90.1%
MG
Mario Gabelli
GAMCO Investors
0.02%$2,755,549▼ -58.4%
JY
Jeff Yass
Susquehanna International Group
0.01%$70,932,026▲ +60.9%
KF
Ken Fisher
Fisher Investments
0%$14,235,025▼ -26%

Frequently asked questions

How much is Boston Scientific Corp (BSX) stock?

Boston Scientific Corp shares trade at $45.69, -0.70% over the last trading day. The price is delayed.

What is the market cap of Boston Scientific Corp?

The market cap of Boston Scientific Corp is about $66.2B and its price-to-earnings ratio (P/E) is 18.5.

How has Boston Scientific Corp stock performed over the last year?

The Boston Scientific Corp share price changed by -54.81% over 12 months and by +5.94% over 5 years.

Which big investors hold Boston Scientific Corp?

According to the latest 13F filings, 18 of 87 tracked investors hold Boston Scientific Corp, for example Lee Ainslie, Jim Simons, Cliff Asness.

When will Boston Scientific Corp report its next results?

The next earnings report of Boston Scientific Corp is expected on 28 Oct 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms (Czech)Privacy (Czech)Cookies (Czech)

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

  • ✓Out of 100 USD of revenue, 17 USD is left as net profit.
  • ✓It earns 15 USD a year on every 100 USD of invested capital (ROE).
  • ✓Revenue grew 16.5% a year over 3 years.
  • ✓The analysts' average target is 27% above the price.
  • What to watch
    • Nothing notable from the statements.

    The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

    Is the stock expensive?

    Fairly cheap

    For 1 USD of annual earnings you pay 18.5 USD. Based on next year's estimates 13.5 USD.

    P/E
    18.5×
    P/S
    3.2×
    EV/EBITDA
    13.8×

    Is the company growing?

    Growing
    22
    23
    24
    25

    Revenue over 3 years grew 16.5% a year. Last year 7.5%.

    Does it make money?

    Good
    • Cost of sales 31
    • Research 10.2
    • Operations and selling 39.0
    • Taxes and other 5.3
    • Net profit 14.4

    Out of 100 USD of revenue, 14.4 USD is left as net profit.

    Is it financially healthy?

    Mostly
    Cash
    539M USD
    Debt
    12.6B USD
    Free CF
    2.5B USD

    It could repay its net debt from free cash flow in 4.9 years.

    Does it pay a dividend?

    No dividend

    The company pays no dividend. It reinvests the money or holds it.

    What do analysts expect?

    Buy
    Average target
    57.82 USD
    Vs price
    +27%

    28 analysts. Their opinion is not a recommendation by FinBoss.io.

    Which big investors hold it?

    18 of 87

    Among the tracked investors, Lee Ainslie, Jim Simons, Cliff Asness and others hold the stock according to 13F filings.

    Revenue and net profit (USD B)

    Margins (% of revenue)

    Free cash flow and capex (USD B)

    Cash and debt (USD B)

    Earnings per share (EPS, USD)

    Latest quarters (USD B)

    Ratios

    P/E
    18.5×
    Forward P/E
    13.5×
    P/B
    2.7×
    P/S
    3.2×
    PEG
    0.64
    EV/EBITDA
    13.8×
    Gross margin
    69.2%
    Operating margin
    22.9%
    Net margin
    17.5%
    ROE
    15.3%
    ROA
    6.2%
    Debt / equity
    0.5×
    Current ratio
    1.2×
    Revenue growth
    7.5%
    Earnings growth
    15.1%
    Beta
    0.58
    Dividend
    0.00%
    Payout ratio
    0%